REVIEW

Overcoming barriers to the clinical utilization of iPSCs: reprogramming efficiency, safety and quality

Suying Cao¹, Kyle Loh², Yangli Pei¹, Wei Zhang¹, Jianyong Han¹ ✉

¹ State Key Laboratory for Agrobiotechnology, College of Biological Sciences, China Agricultural University, Beijing 100193, China

² Stem Cell and Developmental Biology, Genome Institute of Singapore, 138672, Singapore

✉ Correspondence: hanjy@cau.edu.cn

Received August 9, 2012 Accepted September 11, 2012

ABSTRACT

Differentiated cells can be reprogrammed into pluripotent stem cells, known as “induced pluripotent stem cells” (iPSCs), through the overexpression of defined transcription factors. The creation of iPSC lines has opened new avenues for patient-specific cell replacement therapies for regenerative medicine. However, the clinical utilization of iPSCs is largely impeded by two limitations. The first limitation is the low efficiency of iPSCs generation from differentiated cells. The second limitation is that many iPSC lines are not authentically pluripotent, as many cell lines inefficiently differentiate into differentiated cell types when they are tested for their ability to complement embryonic development. Thus, the “quality” of iPSCs must be increased if they are to be differentiated into specialized cell types for cell replacement therapies. Overcoming these two limitations is paramount to facilitate the widespread employment of iPSCs for therapeutic purposes. Here, we summarize recent progress made in strategies enabling the efficient production of high-quality iPSCs, including choice of reprogramming factors, choice of target cell type, and strategies to improve iPSC quality.

KEYWORDS iPSCs, reprogramming, embryonic stem cells, efficiency and quality

INTRODUCTION

The zygote and the embryonic blastomeres are totipotent cells, as they are capable of generating all embryonic and

extraembryonic tissues that give rise to an entire organism. After 4.5 days of embryonic development, these totipotent cells give rise to three distinct cell types that comprise the blastocyst-stage embryo: the epiblast, the primitive endoderm, and the trophectoderm. Of these blastocyst cell types, only the cells of epiblast retain the capacity to generate all cell types of the three fetal germ layers: the definitive endoderm, mesoderm, and definitive ectoderm, as well as the primordial germ cells (PGC), the founder cells of male and female gametes. Given the capacity of epiblast to give rise to all fetal cell types, it is pluripotent.

Embryonic stem (ES) cells, cultured cell lines explanted from the epiblast, are also pluripotent, as they are capable *in vitro* of generating cell types from all three fetal germ layers, as well as differentiating into male and female germ cells (Wobus and Boheler, 2005). When transplanted back into the early embryo into their native environment, ES cells are receptive to developmental patterning signals and they subsequently differentiate into fetal cell types and contribute to fetal development. The pluripotency of ES cells are lost as they differentiate to generate their differentiated progeny.

Nevertheless, differentiated cells can be coerced to re-attain an unrestricted pluripotent state. Herein, we refer to this process as “pluripotent reprogramming”. There are different strategies that have been used to induce the conversion of a differentiated cell into a pluripotent state, including nuclear transfer, fusion with pluripotent cells, co-culture with cell extracts, culture-induced reprogramming, and overexpression of defined transcription factors (Hochedlinger and Jaenisch, 2006; Takahashi and Yamanaka, 2006).

Somatic cell nuclear transfer (SCNT), whereby the nu-

cleus of a differentiated cell is transplanted into an enucleated oocyte or zygote, recreates something akin to a totipotent cell. The differentiated gene expression program of the nucleus of the differentiated cell is erased by nuclear factors present in the cytoplasm of the enucleated oocyte, and the presence of these oocyte nuclear factors reinstates a totipotent gene expression program within the new hybrid cell formed by nuclear transfer. The resultant totipotent cell resumes normal embryonic development and forms a blastocyst from which ES cells can be derived. Thus, SCNT allows for the indirect reprogramming of a differentiated cell into a pluripotent cell. Nevertheless, there are technical and ethical issues in applying SCNT to human cells to create pluripotent human cells through this method (Hochedlinger and Jaenisch, 2006; Yamanaka, 2007).

Fusion of a differentiated cell with a pluripotent cell to reprogram the former into a pluripotent cell is also undesirable, as the resultant cell has a tetraploid karyotype. Reprogramming of differentiated cells by exposure to pluripotent cell extracts has been unsuccessful to date in creating authentic pluripotent cells, and reprogramming by specific culture conditions is limited to germ cell lines (Hochedlinger and Jaenisch, 2006).

To date, the most compelling method to achieve pluripotent reprogramming is through the overexpression of pluripotency-associated transcription factors within differentiated cells. Similar to how in SCNT that oocyte nuclear factors enter into the differentiated cell's nucleus to construct a totipotent gene expression program, in this approach to pluripotent reprogramming, the overexpressed pluripotency-associated transcription factors enter the nucleus of the differentiated cell and instate a pluripotential gene expression program.

In the original report of using transcription factor overexpression to achieve pluripotential reprogramming, Takahashi and Yamanaka were able to reprogram mouse fibroblasts into pluripotent stem cells, known as "induced pluripotent stem cells" (iPSCs), by the overexpression of four pluripotency-associated transcription factors (*Oct4*, *Sox2*, *Klf4*, and *c-Myc*) (Takahashi and Yamanaka, 2006).

Our capability to create iPSCs through transcription factor overexpression has yielded several outstanding benefits. Firstly, the creation of iPSCs through the reprogramming of adult cells allows for the creation of pluripotent stem cell lines bereft of any embryonic tissues or oocytes, thus circumventing many previous ethical objections to the derivation of ES cells from embryos. Secondly, the derivation of "patient specific" iPSCs from the adult tissues of human patients creates immune-matched iPSC lines that are autologous to the donor patient; any differentiated progeny cells generated from these patient-specific iPSC lines are immunocompatible to the patient and thus can be used in a cell replacement therapy without permanent immunosuppression. Finally, the creation of patient-specific iPSC lines from patients afflicted with cer-

tain genetic diseases allows for the *in vitro* modeling of these diseases. Other benefits of iPSC research are expertly reviewed elsewhere.

Recent advances in iPSC research are summarized in this review with a focus on different strategies that have been used to reprogram differentiated cells into iPSCs, the identification of nuclear factors and chemical compounds that can enhance the efficiency of pluripotential reprogramming, and lastly, the identification of factors which uniformly improve the "quality" of iPSCs and allow for more consistent creation of authentically pluripotent iPSC lines. The potential mechanisms of direct reprogramming at the molecular and biochemical levels and future directions of iPSC research are also discussed.

STRATEGIES FOR IPSC GENERATION

A variety of strategies exist for direct reprogramming differentiated cells to pluripotent state, all of which rely on overexpression of particular transcription factors (Table 1).

One question that has been well-addressed by the field is what is the best technical method by which to overexpress these reprogramming transcription factors within the starting cells. The production of iPSCs has so far been achieved through nucleic-acid-based delivery of the reprogramming factors (Maherali and Hochedlinger, 2008). Initial generations of mouse and human iPSCs employed retroviral vectors (Takahashi and Yamanaka, 2006; Takahashi et al., 2007) and constitutive lentiviruses (Blelloch et al., 2007; Yu et al., 2007), while later generations were produced using inducible lentiviruses (Brambrink et al., 2008; Stadtfeld et al., 2008b). Residual expression of integrated copies of reprogramming factors in iPSCs can affect the gene expression and potentially biological properties of the resulting iPSC derivatives. These viral systems, however, have been criticized for their permanent integration into the genome, and endeavors to make iPSCs more therapeutically applicable have led to the pursuit of non-integrating approaches (Maherali and Hochedlinger, 2008).

The first reports at direct reprogramming employed Moloney-based retroviral vectors that are known to undergo silencing in the ESC state (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007); this self-silencing property provided an advantage for initial attempts as the temporal requirement of factor expression, which was defined that proviral silencing in embryonic stem cells requires the histone methyltransferase Eset (Maherali and Hochedlinger, 2008; Matsui et al., 2010). There are several drawbacks for the genome integration system for example their infectivity is limited to dividing cells, thus restricting the range of cell types that can be reprogrammed; silencing occurs gradually during the course of iPSC induction, resulting in a lowered efficiency of conversion compared to nonsilencing viral methods and iPSCs made with retroviruses often maintain viral gene ex-

Table 1 Summary of strategies enabling the production of iPSCs

Strategy		Characters	References
Genomic integration	Moloney-based retrovirus	Silenced in pluripotent cells; genomic integration; limited to dividing cells	Takahashi and Yamanaka, 2006
	HIV-based lentivirus; constitutive system	Genomic integration; lack of silencing in pluripotent state; transduction of both dividing and nondividing cells	Blelloch et al., 2007; Yu et al., 2007; Brambrink et al., 2008
	Inducible system	Genomic integration; possibility of leaky expression; temporal control over factor expression	Brambrink et al., 2008; Stadtfeld et al., 2008b
Free of genetic modification	Transient transfection	No viral components, low frequency of genomic integration, technically simple procedure but multiple rounds of transfection are required, delayed kinetics of reprogramming	Okita et al., 2008
	Lentiviral vectors + Cre	Efficient reprogramming and vector deletion but Vector DNA external to the loxP sites remain integrated	Chang et al., 2009; Soldner et al., 2009
	Adenoviral vector, Episomal vectors, Sendai vectors	Low frequency of genomic integration, delayed kinetics of reprogramming, some generation of tetraploid cells	Stadtfeld et al., 2008c; Fusaki et al., 2009; Gonzalez et al., 2009
	piggyBac transposon	Precise deletion possible, excision may be inefficient and laborious	Kaji et al., 2009; Woltjen et al., 2009
	Protein transduction	Direct delivery of transcription factors avoids complications of nucleic-acid-based delivery, but not yet reported for iPSC production	Bosnali and Edenhofer, 2008
	Small molecules	No genetic modification, still requires at least one factor to be transduced	Huangfu et al., 2008a; Shi et al., 2008b; Ichida et al., 2009; Lyssiotis et al., 2009

pression thus limiting their utility (Maherali and Hochedlinger, 2008). Although iPSCs can be generated by constitutive lentiviruses, their poor silencing within pluripotent cells make them less suitable for direct reprogramming attempts (Blelloch et al., 2007; Yu et al., 2007; Brambrink et al., 2008). Drug-inducible lentiviruses have provided a more attractive approach, as they permit temporal control over factor expression. This approach creates a defined system for studying reprogramming mechanisms and allows screening of genetically homogeneous cells for compounds that can replace any transcription factor that enhance reprogramming efficiency or required for iPS cell derivation (Wernig et al., 2008; Markoulaki et al., 2009; Wu et al., 2009). In these systems, proviruses carrying drug-inducible reprogramming factors used to derive 'primary' iPSCs were segregated through germ line transmission, generating mice and cells carrying subsets of the reprogramming factors. Drug treatment produced 'secondary' iPS cells with over 100-fold increase efficiency only when the missing factor was introduced (Markoulaki et al., 2009).

Methods to overexpress the reprogramming factors that rely on genomic integration within the starting cells have earned much criticism, as the resultant iPSCs also carry the same genomic integrations. The very presence of viral integrations within the genome elicits insertional mutagenesis and reactivation of proximal oncogenes, thus drastically altering cellular properties such as proliferation rate (Kustikova et al., 2005). Furthermore, after such iPSCs are differentiated

and the pluripotent state is exited, the silenced integrated reprogramming factors can be reactivated within the subsequent differentiated cells—thus, when such iPSCs are used to form chimeras, the resultant chimeras had a proclivity for tumorigenesis, likely due to spontaneous reactivation of the reprogramming factor *c-Myc*, which is an oncogene (Nakagawa et al., 2008).

Though it was originally suggested that the very process of iPSC generation might entail transgene integration into particular loci, it was found shortly thereafter that there are no common integration sites amongst various retrovirally-induced iPSC lines, suggesting that transgene integration is not a necessary reprogramming step and that generation of insertion-free iPSCs is possible (Aoi et al., 2008; Varas et al., 2009). This notion has been confirmed by a series of studies. Yu et al. generated human iPS cells with the use of nonintegrating episomal vectors. After removal of the episome, iPS cells completely free of vector and transgene sequences are derived that are similar to human embryonic stem (ES) cells in proliferative and developmental potential (Yu et al., 2009). Stadtfeld et al. derived mouse induced pluripotent stem (iPS) cells from fibroblasts and liver cells by using nonintegrating adenoviruses transiently expressing *Oct4*, *Sox2*, *Klf4*, and *c-Myc*. These adenoviral iPS (adeno-iPS) cells show DNA demethylation characteristic of reprogrammed cells, express endogenous pluripotency genes, form teratomas, and contribute to multiple tissues, including the germ line, in chimeric mice (Stadtfeld et al.,

2008c). Just by repeated transient transfection of plasmids carrying the reprogramming factors, Okita et al. also attained insertion-free mouse iPS similar to ES cells.

Such episomal, adenoviral, and transient transfection means to deliver the reprogramming factors address a critical safety concern for the potential use of iPS cells in regenerative medicine (Okita et al., 2008). Although the several methods above are transient and minimize the potential for insertion mutagenesis, it should be noted that they are extremely inefficient in reprogramming cells as compared to traditional integrating vector strategies.

Other groups have exploited lentiviral vectors flanked by loxP sites as factor delivery vehicles, such that Cre-mediated recombination in the resultant iPSC lines could excise the integrated transgenes (although it should be noted that the loxP sites themselves remain in the genome) (Chang et al., 2009; Soldner et al., 2009). Another recent approach has involved piggyBac transposition, wherein the reprogramming factors are delivered in a piggyBac transposon that can be subsequently induced to integrate or excise from the genome upon transient expression of a transposase enzyme (Kaji et al., 2009; Woltjen et al., 2009). Unlike the above loxP-based lentiviral system, the piggyBac transposition system does not leave behind any genetic material in the genome after transposon excision.

REPROGRAMMING WITH DIFFERENT FACTORS OF TRANSCRIPTION FACTORS

In their original report where Takahashi and Yamanaka that found that transcription factor overexpression was capable of reprogramming mouse fibroblasts, they screened 24 transcription factors, intracellular signaling pathway components, and epigenetic regulators believed to be important in safeguarding the pluripotency of ES cells. Through iterative experiments, they eventually found that all factors save four were dispensable for reprogramming—these four factors became known as the classical quartet of pluripotential reprogramming factors; *Oct4*, *Sox2*, *Klf4*, and *c-Myc* (Takahashi and Yamanaka, 2006). This classical cocktail of reprogramming factors has been shown to induce pluripotency within a multitude of mouse cell types, as well as rhesus monkey (Li et al., 2009b; Liao et al., 2009), pig (Esteban et al., 2009; Ezashi et al., 2009; Wu et al., 2009; West et al., 2010) and human cells (Takahashi et al., 2007; Yamanaka, 2007).

Permutations of this classic four-factor combination have been used to successfully reprogram differentiated cells to a pluripotent state (Table 2). For example, *Sox1* and *Sox3* have been found to be able to substitute for *Sox2*, albeit with a decrease in reprogramming efficiency; *Klf2* can replace *Klf4*, and *L-Myc* and *N-Myc* were found to be able to replace *c-Myc* (Blelloch et al., 2007; Nakagawa et al., 2008). Yu et al. was also able to generate human iPSCs from human fibroblasts

through a different set of factors, namely *Oct4*, *Sox2*, *Nanog*, and *Lin28* (Yu et al., 2007).

Later, *c-Myc* was found to be dispensable for the reprogramming process, thus further narrowing down the list of classical reprogramming factors to three—*Oct4*, *Sox2*, and *Klf4* (Blelloch et al., 2007).

Certain reprogramming factors have been found to be dispensable when cell types endogenously expressing these reprogramming factors are used, thus further reducing the number of necessary factors. For example, human and mouse neural stem cells already express *Sox2*, *Klf4*, and *c-Myc*; thus, they can be reprogrammed by singular overexpression of *Oct4* (Kim et al., 2008, 2009b).

Other unrelated pluripotency-associated transcription factors have also been shown to be capable of reprogramming cells. For example, we have found that *Klf4* can be replaced by the orphan nuclear receptor *Esrrb*, thus allowing for reprogramming with only *Oct4* and *Sox2* (Feng et al., 2009a). Overexpression of the orphan nuclear receptor *Nr5a2* can replace *Oct4*, thus allowing for reprogramming with only *Sox2* and *Klf4* (Heng et al., 2010).

Of particular interest, transcription factor overexpression is a feasible approach to establish pluripotent stem cell lines for species in which it has been difficult to establish ES cell lines from the early embryo (Trounson, 2009; Wu et al., 2009). For example, ES cell lines of many species, such as pig, cow, goat, and sheep have been long sought-after, and many efforts to produce ES cell lines for these species over the past two decades have proven to be unsuccessful (Keefer et al., 2007).

Despite this, pluripotent stem cell lines for the rat, pig and monkey in the form of iPSC lines have been derived through the overexpression of *Oct4*, *Sox2*, *Klf4*, and *c-Myc* from these species (Liu et al., 2008; Esteban et al., 2009; Ezashi et al., 2009; Li et al., 2009b; Liao et al., 2009; Wu et al., 2009). However, we note that some caution must be taken when considering these iPSC lines from such species, because the pluripotential character of such species' iPSC lines is not comparable with the pluripotent character of conventional mouse ES and iPSC cell lines. For example, pig iPSCs do not exhibit as robust reactivation of endogenous pluripotency genes as mouse iPSCs, and they are incapable of silencing integrated genes (Esteban et al., 2009; Ezashi et al., 2009; Wu et al., 2009). Nevertheless, porcine iPSCs derived from mesenchymal cells are capable of contribution to all three germ layers after injection into the early embryo, affirming that they at least are capable of multilineage differentiation (West et al., 2010).

CHOICE OF STARTING CELL TYPE

As aforementioned, the choice of starting cell type to be used for reprogramming is impactful. Cells that already endogenously express certain reprogramming factors at appropriate

levels may not require overexpression of these factors during the reprogramming process. Furthermore, stem cells and progenitors often have a more globally permissive chromatin structure to facilitate ready access to multilineage differentia-

Table 2 Different combinations of transcription factors that induce nuclear reprogramming

Species	Combination of factors	Cell types	Comments	Reference
Mouse	OSKMc	Most of the cell types including terminal differentiated B and T cells	Yamanaka's classical cocktail of reprogramming factors	Takahashi and Yamanaka, 2006; Aoi et al., 2008; Hanna et al., 2008; Kim et al., 2008; Stadtfeld et al., 2008a
	OSKMn	Fibroblast	nMyc and cMyc are largely interchangeable and nMyc has been reported to be less tumorigenic than cMyc in <i>in vitro</i> assays of transformation	Blelloch et al., 2007
	OSKT	Fibroblast	Tbx3 can improve the quality of iPS cells due to its regulation of pluripotency associated and reprogramming factors	Han et al., 2010
	OSEMc	Fibroblast	Esrrb is a orphan nuclear receptor, it may mediate reprogramming through the upregulation of ES-cell-specific genes	Feng et al., 2009a
	SKNrMc	Fibroblast	Nr5a2 shares many common gene targets with Sox2 and Klf4, can upregulate Nanog in ES cells	Heng et al., 2010
	OSK	Fibroblast, hepatocytes and neural stem cells	Ectopic expression of c-Myc causes tumorigenicity in chimeric offspring	Nakagawa et al., 2008
	OSE	Fibroblast	Low efficiency	Feng et al., 2009a
	SKNr	Fibroblast	Low efficiency	Heng et al., 2010
	OK	Neural stem cell	Neural stem cells express higher endogenous levels of Sox2 and c-Myc than embryonic stem cells	Kim et al., 2008
	OMc	Neural stem cell	Neural stem cells express higher endogenous levels of Sox2 and Klf4	Kim et al., 2008
	O	Neural stem cell	Neural stem cells express higher endogenous levels of Sox2 and Klf4	Kim et al., 2009b
Human	OSKMc	Most of the cell types	Yamanaka's classical cocktail of reprogramming factors	Takahashi et al., 2007; Aasen et al., 2008; Lowry et al., 2008; Park et al., 2008; Loh et al., 2009
	OSNL	Dermal fibroblasts	Yu's cocktail for human direct reprogramming	Yu et al., 2007
	OSK	Dermal fibroblasts	Myc is independent for human direct reprogramming	Takahashi et al., 2007; Huangfu et al., 2008b
	OKN	Dermal fibroblasts	Low efficiency	Yu et al., 2007
	OKL	Dermal fibroblasts	Low efficiency	Yu et al., 2007
	OS + VPA	Dermal fibroblasts	Valproic acid (VPA), a histone deacetylase inhibitor, enables reprogramming of primary human fibroblasts with only two factors, Oct4 and Sox2	Huangfu et al., 2008b
	OKMc	Neural stem cell	Neural progenitor cells expressed high levels of endogenous Sox2 and thus did not require viral Sox2 expression for reprogramming into iPS cells	Eminli et al., 2008; Kim et al., 2008
	O	Neural stem cell	Neural stem cells express higher endogenous levels of Sox2 and Klf4	Kim et al., 2008; Kim et al., 2009a
Rat	OSKMc	Fibroblast	Rat adult cell can be reprogrammed to pluripotent state by mouse and human transcription factors	Liu et al., 2008
Monkey	OSKMc	Fibroblast	Monkey iPS cells need further test of chimera contribution	Li et al., 2009b; Liao et al., 2009
Pig	OSKMc	Fibroblast	Pig adult cell can be reprogrammed to pluripotent state by human transcription factors	Esteban et al., 2009; Ezashi et al., 2009; Wu et al., 2009; West et al., 2010
	OSKMcNL	Mesenchymal cells		

Note: O, Oct4; S, Sox2; K, Klf4; Mc, c-Myc; Mn, n-Myc; E, Esrrb; Nr, Nr5a2; N, Nanog; L, Lin28

tion programs, thus making them more amenable to reprogramming. Additionally, differentiated cells with extensive self-renewal capabilities or that express certain pluripotency markers or transcriptional regulators may also be more inclined towards pluripotential reprogramming.

Through conventional reprogramming approaches, human and mouse fibroblasts can only be reprogrammed with a 0.01%–0.05% efficiency (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007). However, results from multiple independent laboratories indicated that neural stem cells (Kim et al., 2008), hematopoietic stem cells (Eminli et al., 2009), meningiocytes from the mouse meningeal membranes (Qin et al., 2008) and primary keratinocytes from plucked hair (Aasen et al., 2008) are more efficiently reprogrammed utilizing the same reprogramming protocols (Table 3).

For at least some of these cell types, it is likely that their increased proclivity for reprogramming is due to endogenous expression of the reprogramming genes. For example, human keratinocytes already express very high levels of *Klf4* and *c-Myc*, and they reprogram two orders of magnitude more efficiently than their fibroblast counterparts (Aasen et al., 2008). Mouse meningeal membrane cells already express *Sox2*, thus providing a mechanistic explanation for their relatively high reprogramming efficiency (Qin et al., 2008).

Conversely, particular differentiated cell types appear to be more refractory to reprogramming. For example, efficient reprogramming of terminally-differentiated B lymphocytes requires knockdown of the B lymphocyte transcription factor *Pax5* or overexpression of the myeloid transcription factor *C/EPBa* to destabilize the firmly-entrenched B cell transcriptional program prior to reprogramming (Hanna et al., 2008).

Several laboratories have established differentiated cell lines that already uniformly carry doxycycline-inducible copies of the reprogramming genes; these cell lines efficiently reprogram upon addition of doxycycline and their reprogram-

ming efficiency does not depend on variable efficiency by which the reprogramming factors can be overexpressed using viral vectors (Hanna et al., 2008). Thus, true reprogramming efficiency of these cells invariant of viral infection efficiency can be ascertained. Such high-efficiency “secondary systems” are attained through iPSCs that have been generated with integrated, doxycycline-inducible reprogramming factors; these “primary” iPSCs are differentiated into differentiated cells, such that addition of doxycycline reprograms these cells into “secondary” iPSCs.

Irrespective of what cell types are ideal for highly efficient pluripotent reprogramming, if we wish to derive patient-specific iPSC lines from human patients, our choice of starting cell type must be predicated on what cell types we can routinely explant from such patients. For example, though neural stem cells reprogram with extremely high efficiency, it would be infeasible to routinely explant neural stem cells from human patients. To this end, a recent breakthrough has been the induction of human iPSCs from human mobilized CD34+ peripheral blood cells (Loh et al., 2009). Our capability to attain iPSCs from hematopoietic cells enables the production of patient-specific iPSCs from blood samples taken from such patients.

Enhancing reprogramming efficiency by alternative factors

The efficiency of pluripotential reprogramming can be enhanced by the inclusion of various other factors besides pluripotent transcription factors. These alternative factors, including microRNAs and chemical compounds, either safeguard the pluripotential identity of ES cells (and thus are likely to impose pluripotency within a differentiated cell) or else play more specific roles in facilitating the reprogramming process but not maintaining pluripotency after it is established (Table 4).

Table 3 The choice of cell type for iPSCs

Species	Cell types	Efficiency	Reference
Mouse	Embryonic fibroblast and adult tail fibroblast	0.01%–0.05%	Takahashi and Yamanaka, 2006
	Adult mouse hepatocytes and gastric epithelial cells		Aoi et al., 2008
	Pancreatic β -cells	0.1%–0.2%	Stadtfeld et al., 2008a
	Meningiocytes	0.5%–0.8%	Qin et al., 2008
	Mature B-lymphocytes	3%	Hanna et al., 2008
	Neural stem cells	3.6%	Kim et al., 2008; Eminli et al., 2009
Human	Hematopoietic stem cells	28%	
	IMR90 fetal fibroblasts; mesenchymal and myeloid cells from human OCT4 knock-in H1 ES cells	0.01%–0.05%	Yu et al., 2007
	Dermal fibroblasts and BJ cells	0.02%–0.05%	Takahashi et al., 2007
	CD34+ mobilized human peripheral blood cells	0.01%–0.02%	Lowry et al., 2008
	Fetal, neonatal and adult fibroblasts	0.1%	Loh et al., 2009
	Primary keratinocytes from plucked hair	0.36%	Park et al., 2008; Aasen et al., 2008
Monkey	Adult rhesus monkey fibroblasts	<0.01%	Liu et al., 2008
Rat	Rat fibroblast	<0.01%	Li et al., 2009b; Liao et al., 2009
Pig	Pig fibroblast	<0.01%	Esteban et al., 2009; Ezashi et al., 2009; Wu et al., 2009; West et al., 2010
	Mesenchymal cells		

Table 4 Factors used to enhance direct reprogramming efficiency

Factors		Comments	References
MicroRNAs	Mir-302	mir-302, which is expressed abundantly in human ESCs, is able to convert human cancer cells into an ES-like pluripotent state, also maintain this state under a feeder-free cultural condition	Lin et al., 2008
	Mir-291-3p; Mir-294, 295	The miRNAs increase the efficiency of reprogramming by Oct4, Sox2 and Klf4, but not by these factors plus cMyc; induce a homogeneous population of iPS cell colonies comparing with cMyc	Judson et al., 2009
	Inhibition of the let-7 family	let-7 miRNAs highly expressed in somatic cells—can suppress self-renewal in Dgcr8 ^{-/-} but not wild-type ESCs, let-7 inhibits whereas ESCC miRNAs indirectly activate numerous self-renewal genes and inhibition of the let-7 family promotes de-differentiation of somatic cells to induced pluripotent stem cells	Melton et al., 2010
Chemicals	2i,CHIR99021+ PD0325901	Dual inhibition of MEK and GSK3, together with LIF, promote ground state pluripotency in OK pre-iPSCs in mouse neural stem cells	Silva et al., 2008
	BIX-01294	G9a histone methyltransferase inhibitor, can replace sox2 in mouse fibroblast reprogramming and can enhance efficiency of reprogramming and replace sox2 in neural stem cells	Shi et al., 2008a, 2008b
	BayK8644	L-type calcium channel agonist, BIX-01294 and BayK8644 combination with factors OK enhance reprogramming efficiency	Shi et al., 2008a
	RG108	DNA methyltransferase inhibitors, BIX-01294 and RG108 combination with factors OK enhance reprogramming efficiency 30 times more than OK	Shi et al., 2008a
	5'-azaC	DNA methyltransferase inhibitor, increase efficiency and full reprogramming	Huangfu et al., 2008a
	Dexamethasone	Steroid glucocorticoid, enhance the effect of 5'-azacytidine	Huangfu et al., 2008a
	VPA	Histone deacetylase inhibitor, increase efficiency by more than 100-fold and replace Klf4 and Myc	Huangfu et al., 2008a, 2008b
	TSA	Histone deacetylase inhibitor, increase reprogramming efficiency in nuclear transfer and iPSCs	Kishigami et al., 2006; Huangfu et al., 2008a
	SAHA	Histone deacetylase inhibitor	Huangfu et al., 2008a
	A-83-01	TGF- β inhibitor, together with LIF and 2i to maintain mESC like rat and human iPSCs	Li et al., 2009b
	Vitamin C	Vitamin C enhances the reprogramming efficiency of mouse and human fibroblasts transduced with three OSK or four OSKM factors and vitamin C can alleviate cell senescence by p53 repression and may accelerate reprogramming by synergizing with epigenetic regulators.	Esteban et al., 2010; Shi et al., 2010
Signaling pathway	Wnt	Cyclic activation of Wnt/beta-catenin signaling in ESCs with Wnt3a strikingly enhances the ability of ESCs to reprogram somatic cells after fusion; Wnt3a conditioned medium promoted the reprogramming OSK-MEFs by 20 fold	Lluis et al., 2008; Marson et al., 2008
	P53	OSKM together with p53 siRNA+UTF1 increase the efficiency of highly AP-positive colony by more than 200 times compared with just using OSKM; The suppression of p53 also increased the efficiency of mouse and human iPS cell generation; In murine cells, Arf, rather than Ink4a, is the main barrier to reprogramming by activation of p53 and p21, whereas, in human fibroblasts, INK4a is more important than ARF.	Zhao et al., 2008; Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009a; Marion et al., 2009; Utikal et al., 2009
	TGF- β	Inhibition of TGF- β signaling promotes the completion of reprogramming through induction of the transcription factor Nanog. Any one of TGF- β inhibitor E-616452 ("RepSox") or E-616451 can replace Sox2	Ichida et al., 2009

Reprogramming is the iterative replacement of the original transcriptional program present within the differentiated starting cell with the program present within a pluripotential cell: a key step is the silencing of the molecular program of

the donor cell. microRNAs are small non-coding RNAs, each of which binds and suppresses hundreds of specific mRNAs, thus drastically altering the transcriptome and molecular constitution of a cell (Melton et al., 2010). Thus, microRNAs are

attractive candidates for factors that can silence the active transcriptional program of the starting cell, thus facilitating reprogramming and establishment of a novel program. To this end, microRNAs expressed within ES cells that possibly suppress differentiation programs have emerged as possible enhancers of reprogramming. Indeed, several ES-expressed microRNAs, such as miR-291-3p, miR-294, miR-295, and miR-302, are capable of enhancing reprogramming efficiency when overexpressed (Lin et al., 2008; Judson et al., 2009; Melton et al., 2010) (Table 4).

A variety of chemical compounds have also been found to enhance reprogramming efficiency or even to replace specific reprogramming transcription factors. These chemical compounds include a DNA methyltransferase inhibitor, histone deacetylase inhibitors, a histone methyltransferase inhibitor, a MAPK/ERK inhibitor, a GSK3 inhibitor, a calcium channel agonist, a steroid glucocorticoid, and Vitamin C (Table 4).

Usage of these chemical compounds to potentiate reprogramming is particularly appealing given their ease of use and the fact that they guaranteedly do not introduce any genetic modifications, as do any reprogramming methods that involve delivery of genetic factors. Nevertheless, from a mechanistic perspective, it is currently unknown whether small molecules alone can recapitulate the series of transcriptional and epigenetic changes brought about by the reprogramming transcription factors, thus making it uncertain if one day it will be possible to reprogram differentiated cells solely by a cocktail of chemical compounds. Furthermore, an important caveat to the usage of chemical compounds that are epigenetic modifiers is that their broad and nonspecific effects may elicit an overall dysregulation of gene expression (Maherali and Hochedlinger, 2008; Feng et al., 2009b).

Extracellular signaling pathways such as the Wnt pathway and the TGF- β pathway have also been shown to have a role in reprogramming; specifically, activation of Wnt/ β -catenin signaling likely enhances reprogramming efficiency, whereas inhibition of TGF- β signaling also enhances reprogramming efficiency and can also replace the reprogramming factor Sox2 (Marson et al., 2008; Ichida et al., 2009). Although the mechanistic role by which TGF- β inhibition facilitates reprogramming has remained a topic of debate, the broadly conserved role of Wnt signaling in maintaining human ES cells, mouse ES cells, and a variety of adult stem cells suggests that Wnt activation during reprogramming may directly activate various pluripotency genes (Miyabayashi et al., 2007).

Another recent major factor that has emerged is the tumor suppressor p53. Five recent publications in *Nature* have shown that suppression of the p53 pathway leads to a marked improvement in the efficiency and kinetics of human and mouse cell reprogramming (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009a; Marion et al., 2009; Utikal et al., 2009). Given that p53 is a stress response protein capable of effecting apoptosis or senescence, suppressing p53 overcomes such barriers, likely explaining the

enhanced reprogramming efficiency observed after p53 suppression. Nevertheless, it is important to note that p53 genetic deletion leads to the generation of iPSCs with uniformly increased genomic damage (given the role of p53 in safeguarding genomic stability)(Krizhanovsky and Lowe, 2009); thus its permanent inactivation is undesirable in the production of iPSCs for therapeutic means.

IMPROVING THE QUALITY OF IPS CELLS

Although many reprogramming agents, including transcription factors, chemical compounds, microRNAs and signaling pathway modulators, have been identified to facilitate or potentiate pluripotent reprogramming, very few studies have carefully examined the quality of iPSCs. Although iPSCs have a distinct morphology and express molecular markers similar to ESCs, their capacity for multilineage differentiation after embryo complementation is extremely varied (Wernig et al., 2007; Shi et al., 2008a; Feng et al., 2009a). During reprogramming to pluripotency, there were the events of copy number variation, mutations of protein-coding regions, karyotypic abnormalities and aberrant slicing of imprinting genes in iPS cells (Stadtfeld et al., 2010; Gore et al., 2011; Hussein et al., 2011). This has led to cogent allegations that many iPS cell lines indeed are not authentic pluripotent stem cell lines.

In mouse, iPS cells with good quality can pass germline transmission and can produce fully iPS mice by tetraploid complement. The germline contribution and the ability of producing iPS mice can be as standards to examine the iPS quality. We generated panels of different iPS lines by different combinations of reprogramming factors and assessed whether inclusion of particular factors could lead to a uniform increase in the “quality” of iPS lines. To this end, we found that overexpression of the pluripotency-associated transcription factor *Tbx3* in combination with *Oct4*, *Sox2*, and *Klf4* (“OSK”) led to iPS lines with enhanced contribution to chimeras and enhanced germline contribution as compared to traditional OSK-derived iPS lines (Han et al., 2010). Thus, inclusion of *Tbx3* leads to a significant increase in the “quality” of mouse iPS lines.

What is the molecular mechanism by which *Tbx3* effects a uniform improvement in the pluripotential characteristics of iPS lines? Through genome-wide chromatin immunoprecipitation-sequencing (ChIP-seq) analysis of *Tbx3*-binding sites, we found that in ES cells, *Tbx3* bound the important ES genes *Oct4*, *Sox2*, *Sall4*, *Lefty1*, *Lefty2*, and *Zfp42*, as well as the reprogramming factors *Klf2*, *Klf4*, *Klf5*, *c-Myc*, and *n-Myc*. However, it remains to be determined whether or not overexpression of *Tbx3* during reprogramming actually leads to upregulation of these pluripotency genes (thus increasing iPS “quality”). *Tbx3* is a member of a family of transcription factors that share a highly conserved DNA-binding domain known as the T-domain. *Tbx3* is necessary for safeguarding the pluripotency of mouse ES cells, as its knockdown elicits

differentiation (Ivanova et al., 2006). It appears to have pleiotrophic roles, as it is also required for mammary bud development and limb development (Carlson et al., 2002; Esteban et al., 2009; Graf et al., 2009; Maekawa et al., 2011). Furthermore, overexpression of *Tbx3* in conjunction with *Myc* or oncogenic *Ras* leads to the efficient oncogenic transformation of mouse fibroblasts; it appears that *Tbx3*'s role in oncogenic cooperation is to inhibit the induction of *p53* and *p19^{ARF}* that is typically triggered by *Myc* and *Ras* (Carlson et al., 2002).

Maekawa et al. found that *Glis1* markedly enhances the generation of iPSCs from both mouse and human fibroblasts when it is expressed together with OSK. Even more importantly, this four transcription factors generated mouse iPSCs can form germline-competent chimaeras (Maekawa et al., 2011). To undertake further research of the mechanism, they found *Glis1* promotes multiple pro-reprogramming pathways, including *Myc*, *Nanog*, *Lin28*, *Wnt*, *Essrb* and the mesenchymal–epithelial transition, to promote the direct reprogramming of somatic cells during iPSC generation. In addition, Vitamin C was found to improve the quality of iPS cells by regulation of the Jhdm 1a/1b pathways (Esteban and Pei, 2012).

FUTURE DIRECTIONS

Pluripotential reprogramming by transcription factor overexpression presents an ideal method to generate pluripotent stem cell lines bereft of embryonic tissue. Furthermore, the generation of patient-specific iPSC lines enables autologous cell replacement therapies for human patients, as well as

opportunities to generate novel *in vitro* models of human genetic diseases. Here, we have highlighted two important issues that must be circumvented prior to the widespread therapeutic employment of iPSC technology: namely, the inefficiency of iPSC generation and the inconsistent pluripotent characteristics of many iPSC lines.

Through pluripotential reprogramming may be efficiently achieved through a variety of technical methods, such as method of reprogramming factor delivery, choice of starting cell type, and inclusion of additional genetic factors or chemical compounds, the latter issue—that of iPSC quality—presently remains inadequately addressed. Methods to routinely assess the “quality” of generated iPSC lines remain to be developed as well as factor combinations that lead to a uniform increase in the proportion of authentically pluripotent iPSC lines that are generated.

A defined cadre of transcription factors and epigenetic regulators confer ES cells with their authentic pluripotent condition—we are attaining an increasingly detailed understanding of which nuclear factors safeguard ES cell pluripotency and the mechanisms by which they act to maintain pluripotency. The authentic pluripotency of ES cells should be recreatable within iPSCs by the expression of all nuclear factors that confer ES cells with their own genuine pluripotency. We intuit that a rational strategy to uniformly enhance iPSC quality will involve increasing molecular definition of the factors that underlay ES cell pluripotency combined with the inclusion of such ES cell nuclear factors within the cocktail of factors used to reprogram differentiated cells (Fig. 1).

Figure 1. Exploration of the mechanisms for reprogramming different cell type to unitive high quality iPSCs. Different strategies and factors affect the generating efficiency and quality of iPSCs have been identified and there are still lots of unknown for the mechanisms, which is the key thing we should focus on before the clinic application in future (Graf and Enver, 2009).

ACKNOWLEDGEMENTS

Decribed here is partially funded by Program for New Century Excellent Talents in University (NCET-11-0482) and by the National Key Basic Research and Development Program of China (Nos. 2009CB941003, 2011CBA01102, 2011CBA01001, and 2010CB945404). We would like to thank Professor Bing Lim and Professor Ning Li for their discussions and suggestions.

REFERENCES

- Aasen, T., Raya, A., Barrero, M.J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilic, J., Pekarik, V., Tiscornia, G., et al. (2008). Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. *Nat Biotechnol* 26, 1276–1284.
- Aoi, T., Yae, K., Nakagawa, M., Ichisaka, T., Okita, K., Takahashi, K., Chiba, T., and Yamanaka, S. (2008). Generation of pluripotent stem cells from adult mouse liver and stomach cells. *Science* 321, 699–702.
- Blelloch, R., Venere, M., Yen, J., and Ramalho-Santos, M. (2007). Generation of induced pluripotent stem cells in the absence of drug selection. *Cell Stem Cell* 1, 245–247.
- Bosnali, M., and Edenhofer, F. (2008). Generation of transducible versions of transcription factors Oct4 and Sox2. *Biol Chem* 389, 851–861.
- Brambrink, T., Foreman, R., Welstead, G.G., Lengner, C.J., Wernig, M., Suh, H., and Jaenisch, R. (2008). Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. *Cell Stem Cell* 2, 151–159.
- Carlson, H., Ota, S., Song, Y., Chen, Y., and Hurlin, P.J. (2002). Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. *Oncogene* 21, 3827–3835.
- Chang, C.W., Lai, Y.S., Pawlik, K.M., Liu, K., Sun, C.W., Li, C., Schoeb, T.R., and Townes, T.M. (2009). Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. *Stem Cells* 27, 1042–1049.
- Eminli, S., Foudi, A., Stadtfeld, M., Maherali, N., Ahfeldt, T., Mostoslavsky, G., Hock, H., and Hochedlinger, K. (2009). Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. *Nat Genet* 41, 968–976.
- Eminli, S., Utikal, J., Arnold, K., Jaenisch, R., and Hochedlinger, K. (2008). Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. *Stem Cells* 26, 2467–2474.
- Esteban, M.A., and Pei, D. (2012). Vitamin C improves the quality of somatic cell reprogramming. *Nat Genet* 44, 366–367.
- Esteban, M.A., Wang, T., Qin, B., Yang, J., Qin, D., Cai, J., Li, W., Weng, Z., Chen, J., Ni, S., et al. (2010). Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. *Cell Stem Cell* 6, 71–79.
- Esteban, M.A., Xu, J., Yang, J., Peng, M., Qin, D., Li, W., Jiang, Z., Chen, J., Deng, K., Zhong, M., et al. (2009). Generation of induced pluripotent stem cell lines from Tibetan miniature pig. *J Biol Chem* 284, 17634–17640.
- Ezashi, T., Telugu, B.P., Alexenko, A.P., Sachdev, S., Sinha, S., and Roberts, R.M. (2009). Derivation of induced pluripotent stem cells from pig somatic cells. *Proc Natl Acad Sci U S A* 106, 10993–10998.
- Feng, B., Jiang, J., Kraus, P., Ng, J.H., Heng, J.C., Chan, Y.S., Yaw, L.P., Zhang, W., Loh, Y.H., Han, J., et al. (2009a). Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. *Nat Cell Biol* 11, 197–203.
- Feng, B., Ng, J.H., Heng, J.C., and Ng, H.H. (2009b). Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. *Cell Stem Cell* 4, 301–312.
- Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., and Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* 85, 348–362.
- Gonzalez, F., Barragan Monasterio, M., Tiscornia, G., Montserrat Pulido, N., Vassena, R., Battle Morera, L., Rodriguez Piza, I., and Izpisua Belmonte, J.C. (2009). Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. *Proc Natl Acad Sci U S A* 106, 8918–8922.
- Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., Giorgetti, A., Israel, M.A., Kiskinis, E., et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. *Nature* 471, 63–67.
- Graf, T., and Enver, T. (2009). Forcing cells to change lineages. *Nature* 462, 587–594.
- Han, J., Yuan, P., Yang, H., Zhang, J., Soh, B.S., Li, P., Lim, S.L., Cao, S., Tay, J., Orlov, Y.L., et al. (2010). Tbx3 improves the germ-line competency of induced pluripotent stem cells. *Nature* 463, 1096–1100.
- Hanna, J., Markoulaki, S., Schorderet, P., Carey, B.W., Beard, C., Wernig, M., Creighton, M.P., Steine, E.J., Cassady, J.P., Foreman, R., et al. (2008). Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. *Cell* 133, 250–264.
- Heng, J.C., Feng, B., Han, J., Jiang, J., Kraus, P., Ng, J.H., Orlov, Y.L., Huss, M., Yang, L., Lufkin, T., et al. (2010). The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. *Cell Stem Cell* 6, 167–174.
- Hochedlinger, K., and Jaenisch, R. (2006). Nuclear reprogramming and pluripotency. *Nature* 441, 1061–1067.
- Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., and Yamanaka, S. (2009). Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. *Nature* 460, 1132–1135.
- Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and Melton, D.A. (2008a). Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol* 26, 795–797.
- Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W., and Melton, D.A. (2008b). Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. *Nat Biotechnol* 26, 1269–1275.
- Hussein, S.M., Batada, N.N., Vuoristo, S., Ching, R.W., Autio, R., Narva, E., Ng, S., Sourour, M., Hamalainen, R., Olsson, C., et al. (2011). Copy number variation and selection during reprogramming to pluripotency. *Nature* 471, 58–62.

- Ichida, J.K., Blanchard, J., Lam, K., Son, E.Y., Chung, J.E., Egli, D., Loh, K.M., Carter, A.C., Di Giorgio, F.P., Koszka, K., et al. (2009). A small-molecule inhibitor of *tgf-Beta* signaling replaces *sox2* in reprogramming by inducing *nanog*. *Cell Stem Cell* 5, 491–503.
- Ivanova, N., Dobrin, R., Lu, R., Kotenko, I., Levorse, J., DeCoste, C., Schafer, X., Lun, Y., and Lemischka, I.R. (2006). Dissecting self-renewal in stem cells with RNA interference. *Nature* 442, 533–538.
- Judson, R.L., Babiarz, J.E., Venere, M., and Blelloch, R. (2009). Embryonic stem cell-specific microRNAs promote induced pluripotency. *Nat Biotechnol* 27, 459–461.
- Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., and Woltjen, K. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. *Nature* 458, 771–775.
- Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A., Wahl, G.M., and Belmonte, J.C. (2009). Linking the p53 tumour suppressor pathway to somatic cell reprogramming. *Nature* 460, 1140–1144.
- Keefer, C.L., Pant, D., Blomberg, L., and Talbot, N.C. (2007). Challenges and prospects for the establishment of embryonic stem cell lines of domesticated ungulates. *Anim Reprod Sci* 98, 147–168.
- Kim, J.B., Greber, B., Arauzo-Bravo, M.J., Meyer, J., Park, K.I., Zaehres, H., and Scholer, H.R. (2009a). Direct reprogramming of human neural stem cells by OCT4. *Nature* 461, 649–643.
- Kim, J.B., Sebastiano, V., Wu, G., Arauzo-Bravo, M.J., Sasse, P., Gentile, L., Ko, K., Ruau, D., Ehrlich, M., van den Boom, D., et al. (2009b). Oct4-induced pluripotency in adult neural stem cells. *Cell* 136, 411–419.
- Kim, J.B., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano, V., Arauzo-Bravo, M.J., Ruau, D., Han, D.W., Zenke, M., et al. (2008). Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. *Nature* 454, 646–650.
- Kishigami, S., Mizutani, E., Ohta, H., Hikichi, T., Thuan, N.V., Wakayama, S., Bui, H.T., and Wakayama, T. (2006). Significant improvement of mouse cloning technique by treatment with trichostatin A after somatic nuclear transfer. *Biochem Biophys Res Commun* 340, 183–189.
- Krizhanovsky, V., and Lowe, S.W. (2009). Stem cells: The promises and perils of p53. *Nature* 460, 1085–1086.
- Kustikova, O., Fehse, B., Modlich, U., Yang, M., Dullmann, J., Kamino, K., von Neuhoff, N., Schlegelberger, B., Li, Z., and Baum, C. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. *Science* 308, 1171–1174.
- Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Canamero, M., Blasco, M.A., and Serrano, M. (2009a). The *Ink4/Arf* locus is a barrier for iPS cell reprogramming. *Nature* 460, 1136–1139.
- Li, W., Wei, W., Zhu, S., Zhu, J., Shi, Y., Lin, T., Hao, E., Hayek, A., Deng, H., and Ding, S. (2009b). Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. *Cell Stem Cell* 4, 16–19.
- Liao, J., Cui, C., Chen, S., Ren, J., Chen, J., Gao, Y., Li, H., Jia, N., Cheng, L., Xiao, H., et al. (2009). Generation of induced pluripotent stem cell lines from adult rat cells. *Cell Stem Cell* 4, 11–15.
- Lin, S.L., Chang, D.C., Chang-Lin, S., Lin, C.H., Wu, D.T., Chen, D.T., and Ying, S.Y. (2008). *Mir-302* reprograms human skin cancer cells into a pluripotent ES-cell-like state. *RNA* 14, 2115–2124.
- Liu, H., Zhu, F., Yong, J., Zhang, P., Hou, P., Li, H., Jiang, W., Cai, J., Liu, M., Cui, K., et al. (2008). Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. *Cell Stem Cell* 3, 587–590.
- Lluis, F., Pedone, E., Pepe, S., and Cosma, M.P. (2008). Periodic activation of *Wnt/beta-catenin* signaling enhances somatic cell reprogramming mediated by cell fusion. *Cell Stem Cell* 3, 493–507.
- Loh, Y.H., Agarwal, S., Park, I.H., Urbach, A., Huo, H., Heffner, G.C., Kim, K., Miller, J.D., Ng, K., and Daley, G.Q. (2009). Generation of induced pluripotent stem cells from human blood. *Blood* 113, 5476–5479.
- Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchieu, J., Sridharan, R., Clark, A.T., and Plath, K. (2008). Generation of human induced pluripotent stem cells from dermal fibroblasts. *Proc Natl Acad Sci U S A* 105, 2883–2888.
- Lyssiotis, C.A., Foreman, R.K., Staerk, J., Garcia, M., Mathur, D., Markoulaki, S., Hanna, J., Lairson, L.L., Charette, B.D., Bouchez, L.C., et al. (2009). Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of *Klf4*. *Proc Natl Acad Sci U S A* 106, 8912–8917.
- Maekawa, M., Yamaguchi, K., Nakamura, T., Shibukawa, R., Kodanaka, I., Ichisaka, T., Kawamura, Y., Mochizuki, H., Goshima, N., and Yamanaka, S. (2011). Direct reprogramming of somatic cells is promoted by maternal transcription factor *Glis1*. *Nature* 474, 225–229.
- Maherali, N., and Hochedlinger, K. (2008). Guidelines and techniques for the generation of induced pluripotent stem cells. *Cell Stem Cell* 3, 595–605.
- Marion, R.M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., and Blasco, M.A. (2009). A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. *Nature* 460, 1149–1153.
- Markoulaki, S., Hanna, J., Beard, C., Carey, B.W., Cheng, A.W., Lengner, C.J., Dausman, J.A., Fu, D., Gao, Q., Wu, S., et al. (2009). Transgenic mice with defined combinations of drug-inducible reprogramming factors. *Nat Biotechnol* 27, 169–171.
- Marson, A., Foreman, R., Chevalier, B., Bilodeau, S., Kahn, M., Young, R.A., and Jaenisch, R. (2008). *Wnt* signaling promotes reprogramming of somatic cells to pluripotency. *Cell Stem Cell* 3, 132–135.
- Matsui, T., Leung, D., Miyashita, H., Maksakova, I.A., Miyachi, H., Kimura, H., Tachibana, M., Lorincz, M.C., and Shinkai, Y. (2010). Proviral silencing in embryonic stem cells requires the histone methyltransferase *ESET*. *Nature* 464, 927–931.
- Melton, C., Judson, R.L., and Blelloch, R. (2010). Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. *Nature* 463, 621–626.
- Miyabayashi, T., Teo, J.L., Yamamoto, M., McMillan, M., Nguyen, C., and Kahn, M. (2007). *Wnt/beta-catenin/CBP* signaling maintains long-term murine embryonic stem cell pluripotency. *Proc Natl Acad Sci U S A* 104, 5668–5673.
- Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochizuki, Y., Takizawa, N., and Yamanaka, S.

- (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat Biotechnol* 26, 101–106.
- Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. *Science* 322, 949–953.
- Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H., Lensch, M.W., and Daley, G.Q. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* 451, 141–146.
- Qin, D., Gan, Y., Shao, K., Wang, H., Li, W., Wang, T., He, W., Xu, J., Zhang, Y., Kou, Z., et al. (2008). Mouse meningiocytes express Sox2 and yield high efficiency of chimeras after nuclear reprogramming with exogenous factors. *J Biol Chem* 283, 33730–33735.
- Shi, Y., Despons, C., Do, J.T., Hahm, H.S., Scholer, H.R., and Ding, S. (2008a). Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. *Cell Stem Cell* 3, 568–574.
- Shi, Y., Do, J.T., Despons, C., Hahm, H.S., Scholer, H.R., and Ding, S. (2008b). A combined chemical and genetic approach for the generation of induced pluripotent stem cells. *Cell Stem Cell* 2, 525–528.
- Shi, Y., Zhao, Y., and Deng, H. (2010). Powering reprogramming with vitamin C. *Cell Stem Cell* 6, 1–2.
- Silva, J., Barrandon, O., Nichols, J., Kawaguchi, J., Theunissen, T.W., and Smith, A. (2008). Promotion of reprogramming to ground state pluripotency by signal inhibition. *PLoS Biol* 6, e253.
- Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M., et al. (2009). Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. *Cell* 136, 964–977.
- Stadtfeld, M., Apostolou, E., Akutsu, H., Fukuda, A., Follett, P., Natesan, S., Kono, T., Shioda, T., and Hochedlinger, K. (2010). Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. *Nature* 465, 175–181.
- Stadtfeld, M., Brennand, K., and Hochedlinger, K. (2008a). Reprogramming of pancreatic beta cells into induced pluripotent stem cells. *Curr Biol* 18, 890–894.
- Stadtfeld, M., Maherali, N., Breault, D.T., and Hochedlinger, K. (2008b). Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. *Cell Stem Cell* 2, 230–240.
- Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., and Hochedlinger, K. (2008c). Induced pluripotent stem cells generated without viral integration. *Science* 322, 945–949.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.
- Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663–676.
- Trounson, A. (2009). Rats, cats, and elephants, but still no unicorn: induced pluripotent stem cells from new species. *Cell Stem Cell* 4, 3–4.
- Utikal, J., Polo, J.M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R.M., Khalil, A., Rheinwald, J.G., and Hochedlinger, K. (2009). Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. *Nature* 460, 1145–1148.
- Varas, F., Stadtfeld, M., de Andres-Aguayo, L., Maherali, N., di Tullio, A., Pantano, L., Notredame, C., Hochedlinger, K., and Graf, T. (2009). Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions. *Stem Cells* 27, 300–306.
- Wernig, M., Lengner, C.J., Hanna, J., Lodato, M.A., Steine, E., Foreman, R., Staerk, J., Markoulaki, S., and Jaenisch, R. (2008). A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. *Nat Biotechnol* 26, 916–924.
- Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, B.E., and Jaenisch, R. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature* 448, 318–324.
- West, F.D., Terlouw, S.L., Kwon, D.J., Mumaw, J.L., Dhara, S.K., Hasneen, K., Dobrinsky, J.R., and Stice, S.L. (2010). Porcine induced pluripotent stem cells produce chimeric offspring. *Stem Cells Dev* 19, 1211–1220.
- Wobus, A.M., and Boheler, K.R. (2005). Embryonic stem cells: prospects for developmental biology and cell therapy. *Physiol Rev* 85, 635–678.
- Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen, R., Cowling, R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 458, 766–770.
- Wu, Z., Chen, J., Ren, J., Bao, L., Liao, J., Cui, C., Rao, L., Li, H., Gu, Y., Dai, H., et al. (2009). Generation of pig induced pluripotent stem cells with a drug-inducible system. *J Mol Cell Biol* 1, 46–54.
- Yamanaka, S. (2007). Strategies and new developments in the generation of patient-specific pluripotent stem cells. *Cell Stem Cell* 1, 39–49.
- Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I., and Thomson, J.A. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 324, 797–801.
- Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318, 1917–1920.
- Zhao, Y., Yin, X., Qin, H., Zhu, F., Liu, H., Yang, W., Zhang, Q., Xiang, C., Hou, P., Song, Z., et al. (2008). Two supporting factors greatly improve the efficiency of human iPSC generation. *Cell Stem Cell* 3, 475–479.